New study on DNA transcription uncovers links to … – ASU News Now

February 22, 2023

In a first-of-its-kind study, Arizona State University Professor Michael Lynch joins a multi-institute group of researchers to investigate transcription error rates in human cells and the underlying mechanisms affecting them.

Transcription is the process of copying DNA to RNA. The accuracy of transcription processes varies widely among species, across cell types and within distinct regions of the genome, with profound consequences for health and disease. DNA transcription is a crucial process in the expression of genetic information, as it converts the information stored in DNA into messenger RNA, which can then be translated into proteins. Without transcription, cells would not be able to produce the proteins necessary for their function and survival. A new study estimates the rates of transcription error. Graphic by Jason Drees Download Full Image

The research sheds new light on a foundational process in biology. The results also suggest that high rates of transcription error, observed in specific classes of neurons, are a potential source of neurodegenerative diseases, including Alzheimers disease.

Although we have recently made substantial progress on estimating error rates at the transcriptional level, the next challenge is to establish the connection of such errors with cell health, Lynch says.

The research results appear in the current issue of the journal PNAS.

Professor Lynch directs the Biodesign Center for Mechanisms of Evolution and is a professor in the School of Life Sciences at ASU. He is one of the worlds leading quantitative geneticists, whose research focuses on uncovering the mechanisms driving evolution at the genomic, cellular and organismic levels. He has recently been honored with an ASU Regents Professorship.

The new study analyzes transcription errors in human embryonic stem cells and in mice to unveil the molecular mechanisms governing transcriptional accuracy. The research provides the first estimate of transcriptional error rates in human cells and identifies various genetic and epigenetic factors responsible.

Michael Lynch directs the Biodesign Center for Mechanisms of Evolution and is a professor in the School of Life Sciences at ASU.

The foundations of life hinge on the precise replication and transcription of DNA and the translation of the resultant messenger RNAs. These processes are responsible for accurately passing down and expressing our genetic information, and their fidelity is crucial for maintaining the stability of our genetic code. Despite their importance, the molecular mechanisms behind the faithful transcription of DNA remain largely unknown.

During transcription, the genetic information stored in a gene's DNA sequence is copied into a molecule of messenger RNA (mRNA), which then carries the information out of the nucleus and into the cytoplasm where it can be translated into a functional protein. Transcription errors occur during the process of copying genetic information from DNA to RNA, one of the key steps in gene expression.

These errors can arise from DNA damage, incorrect recognition of the DNA template by the gene-reading mechanism (known as RNA polymerase) or problems with the repair mechanisms that correct errors in the transcription process.

Inaccurate transcription can produce truncated or altered proteins that are unable to perform their normal functions, leading to disease.

Several factors exert a profound influence on rates of transcription error. Some genes are more faithfully transcribed than others, which can be a consequence of their relative length or complexity. Genes are sequences composed of DNAs 4 nucleotides, labelled A, T, C and G.

The study demonstrates they are not transcribed with equal reliability, as A and G transcriptions tend to be more error prone.

The study also reveals that different types of RNA polymerase, the machinery responsible for proofreading DNA during transcription, have significantly differing rates of reliability. The error rate not only differs between types of polymerase, but also between classes of genes being transcribed and even between specific regions of these genes.

Another key factor of accuracy is the rate of transcription. Just as a proofreader is more likely to make mistakes if they race through a page of text, ultra-rapid DNA reading by fast RNA polymerases are more likely to produce errors in transcription.

There are also differences in the behavior and effectiveness of DNA repair proteins, which can fix mistakes in transcription after they have occurred. A new role for one such protein, known as BRCA1, is reported in the study. In addition to BRCA1s role in repairing DNA damage and preventing it from accumulating across the genome, the study indicates this invaluable protein appears to improve transcription fidelity.

Mutations in the BRCA1 gene, which codes for this error-correcting protein, have long been associated with a range of serious health issues, particularly breast cancer and ovarian cancer. BRCA1 mutations have also been linked to other health conditions, including pancreatic cancer, melanoma and fallopian tube cancer.

A mouse model was developed to probe which cell types are most susceptible to producing misfolded proteins due to transcription errors. Neuronal cell types associated with Alzheimers disease display comparatively high transcriptional error rates. One of the effects of this appears to be the generation of a toxic protein form called APP, a precursor to the amyloid plaques that accumulate and cloud the intercellular spaces of the brain and which are a hallmark of Alzheimers disease.

Cells and tissues most prone to transcription errors are identified in the study, revealing that neurons in two critical regions of the brain, CA1 and dentate gyrus, are particularly disposed to DNA alterations or transcriptional mutagenesis. The finding supports the hypothesis that transcription errors contribute to Alzheimer's disease and other potentially devastating effects in the brain.

Such protein aberrations produced by transcription errors may be culprits in other neurodegenerative diseases, including Parkinsons disease, amyotrophic lateral sclerosis and frontotemporal dementia.

The foundation of life lies in the precise replication, transcription and translation of DNA but knowledge about the mechanisms that control the accuracy of transcription remains limited. Ongoing research of this kind will deepen understanding of processes at the heart of biology and may advance new approaches to currently intractable afflictions, such as Alzheimers disease.

More:
New study on DNA transcription uncovers links to ... - ASU News Now

To not love thy neighbor: mechanisms of cell competition in stem … – Nature.com

Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015;16:32944.

Article CAS PubMed PubMed Central Google Scholar

Soteriou D, Fuchs Y. A matter of life and death: stem cell survival in tissue regeneration and tumour formation. Nat Rev Cancer. 2018;18:187201.

Article CAS PubMed Google Scholar

Koren E, Fuchs Y. Modes of regulated cell death in cancer. Cancer Discov. 2021;11:24565.

Article CAS PubMed Google Scholar

Morata G. Cell competition: a historical perspective. Dev Biol. 2021;476:3340.

Article CAS PubMed Google Scholar

Levayer R, Moreno E. Mechanisms of cell competition: themes and variations. J Cell Biol. 2013;200:68998.

Article CAS PubMed PubMed Central Google Scholar

Cosentino K, Garca-Sez AJ. Bax and Bak pores: are we closing the circle? Trends Cell Biol. 2017;27:26675.

Article CAS PubMed Google Scholar

Walczak H. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol. 2013;5:a008698.

Article PubMed PubMed Central Google Scholar

Morata G, Ripoll P. Minutes: mutants of drosophila autonomously affecting cell division rate. Dev Biol. 1975;42:21121.

Article CAS PubMed Google Scholar

Simpson P, Morata G. Differential mitotic rates and patterns of growth in compartments in the Drosophila wing. Dev Biol. 1981;85:299308.

Article CAS PubMed Google Scholar

Cohen B, Simcox AA, Cohen SM. Allocation of the thoracic imaginal primordia in the Drosophila embryo. Development. 1993;117:597608.

Article CAS PubMed Google Scholar

Marygold SJ, Roote J, Reuter G, Lambertsson A, Ashburner M, Millburn GH, et al. The ribosomal protein genes and Minute loci of Drosophila melanogaster. Genome Biol. 2007;8:R216.

Article PubMed PubMed Central Google Scholar

Lindsley DL, Grell EH. Genetic variations of Drosophila melanogaster. Science 1968;162:993993.

Google Scholar

Moreno E, Basler K, Morata G. Cells compete for Decapentaplegic survival factor to prevent apoptosis in Drosophila wing development. Nature. 2002;416:7559.

Article CAS PubMed Google Scholar

Moreno E, Basler K. DMyc transforms cells into super-competitors. Cell. 2004;117:11729.

Article CAS PubMed Google Scholar

de la Cova C, Abril M, Bellosta P, Gallant P, Johnston LA. Drosophila Myc regulates organ size by inducing cell competition. Cell 2004;117:10716.

Article PubMed Google Scholar

Tolwinski NS. Introduction: Drosophila-a model system for developmental biology. J Dev Biol. 2017;5:9.

Article PubMed PubMed Central Google Scholar

Baker NE. Emerging mechanisms of cell competition. Nat Rev Genet. 2020;21:68397.

Article CAS PubMed PubMed Central Google Scholar

Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell. 2010;143:50825.

Article CAS PubMed PubMed Central Google Scholar

Evans M, Kaufman M. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:1546.

Article CAS PubMed Google Scholar

Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 1999;18:614557.

Article CAS PubMed Google Scholar

Vousden KH, Lu X. Live or let die: the cells response to p53. Nat Rev Cancer. 2002;2:594604.

Article CAS PubMed Google Scholar

Tarkowski AK, Witkowska A, Opas J. Development of cytochalasin B-induced tetraploid and diploid/tetraploid mosaic mouse embryos. J Embryol Exp Morphol. 1977;41:4764.

CAS PubMed Google Scholar

Nagy A, Gocza E, Merentes Diaz E, Prideaux VR, Ivanyi E, Markkl M, et al. Embryonic stem cells alone are able to support fetal development in the mouse. Development. 1990;110:81521.

Article CAS PubMed Google Scholar

Horii T, Yamamoto M, Morita S, Kimura M, Nagao Y, Hatada I. P53 suppresses tetraploid development in mice. Sci Rep. 2015;5:8907.

Article CAS PubMed PubMed Central Google Scholar

Bowling S, di Gregorio A, Sancho M, Pozzi S, Aarts M, Signore M, et al. P53 and mTOR signalling determine fitness selection through cell competition during early mouse embryonic development. Nat Commun. 2018;9:1763.

Article PubMed PubMed Central Google Scholar

Zhang G, Xiea Y, Zhou Y, Xiang C, Chen L, Zhang C, et al. P53 pathway is involved in cell competition during mouse embryogenesis. Proc Natl Acad Sci USA. 2017;114:498503.

Article CAS PubMed PubMed Central Google Scholar

Dejosez M, Ura H, Brandt VL, Zwaka TP. Safeguards for cell cooperation in mouse embryogenesis shown by genome-wide cheater screen. Science. 2013;341:15114.

Article CAS PubMed Google Scholar

Sancho M, Di-Gregorio A, George N, Pozzi S, Snchez JM, Pernaute B, et al. Competitive interactions eliminate unfit embryonic stem cells at the onset of differentiation. Dev Cell. 2013;26:1930.

Article CAS PubMed PubMed Central Google Scholar

Clavera C, Giovinazzo G, Sierra R, Torres M. Myc-driven endogenous cell competition in the early mammalian embryo. Nature. 2013;500:3944.

Article PubMed Google Scholar

Hashimoto M, Sasaki H. Epiblast formation by TEAD-YAP-dependent expression of pluripotency factors and competitive elimination of unspecified cells. Dev Cell. 2019;50:13954.

Article CAS PubMed Google Scholar

Daz-Daz C, Fernandez de Manuel L, Jimenez-Carretero D, Montoya MC, Clavera C, Torres M. Pluripotency surveillance by Myc-driven competitive elimination of differentiating cells. Dev Cell. 2017;4:58599.

Article Google Scholar

Ellis SJ, Gomez NC, Levorse J, Mertz AF, Ge Y, Fuchs E. Distinct modes of cell competition shape mammalian tissue morphogenesis. Nature. 2019;569:497502.

Article CAS PubMed PubMed Central Google Scholar

Mesa KR, Rompolas P, Zito G, Myung P, Sun TY, Brown S, et al. Niche-induced cell death and epithelial phagocytosis regulate hair follicle stem cell pool. Nature. 2015;522:9497.

Article CAS PubMed PubMed Central Google Scholar

Lima A, Lubatti G, Burgstaller J, Hu D, Green AP, di Gregorio A, et al. Cell competition acts as a purifying selection to eliminate cells with mitochondrial defects during early mouse development. Nat Metab. 2021;3:1091108.

Article CAS PubMed PubMed Central Google Scholar

Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J. The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer. 2007;6:77.

Article PubMed PubMed Central Google Scholar

Jam FA, Morimune T, Tsukamura A, Tano A, Tanaka Y, Mori Y, et al. Neuroepithelial cell competition triggers loss of cellular juvenescence. Sci Rep. 2020;10:18044.

Article CAS PubMed PubMed Central Google Scholar

Kucinski I, Dinan M, Kolahgar G, Piddini E. Chronic activation of JNK JAK/STAT and oxidative stress signalling causes the loser cell status. Nat Commun. 2017;8:136.

Article PubMed PubMed Central Google Scholar

Nagata R, Nakamura M, Sanaki Y, Igaki T. Cell competition is driven by autophagy. Dev Cell. 2019;51:99112.

Article CAS PubMed Google Scholar

Baumgartner ME, Dinan MP, Langton PF, Kucinski I, Piddini E. Proteotoxic stress is a driver of the loser status and cell competition. Nat Cell Biol. 2021;23:13646.

Article CAS PubMed PubMed Central Google Scholar

Recasens-Alvarez C, Alexandre C, Kirkpatrick J, Nojima H, Huels DJ, Snijders AP, et al. Ribosomopathy-associated mutations cause proteotoxic stress that is alleviated by TOR inhibition. Nat Cell Biol. 2021;23:12735.

Article CAS PubMed PubMed Central Google Scholar

Langton PF, Baumgartner ME, Logeay R, Piddini E. Xrp1 and Irbp18 trigger a feed-forward loop of proteotoxic stress to induce the loser status. PLoS Genet. 2021;17:e1009946.

Article CAS PubMed PubMed Central Google Scholar

Lee CH, Kiparaki M, Blanco J, Folgado V, Ji Z, Kumar A, et al. A regulatory response to ribosomal protein mutations controls translation, growth, and cell competition. Dev Cell. 2018;46:45669.

Article CAS PubMed PubMed Central Google Scholar

Baillon L, Germani F, Rockel C, Hilchenbach J, Basler K. Xrp1 is a transcription factor required for cell competition-driven elimination of loser cells. Sci Rep. 2018;8:17712.

Article CAS PubMed PubMed Central Google Scholar

Ochi N, Nakamura M, Nagata R, Wakasa N, Nakano R, Igaki T. Cell competition is driven by Xrp1-mediated phosphorylation of eukaryotic initiation factor 2. PLoS Genet. 2021;17:e1009958.

Article CAS PubMed PubMed Central Google Scholar

Kiparaki M, Khan C, Folgado-Marco V, Chuen J, Moulos P, Baker NE. The transcription factor Xrp1 orchestrates both reduced translation and cell competition upon defective ribosome assembly or function. Elife 2022;11:e71705.

Article CAS PubMed PubMed Central Google Scholar

Ji Z, Chuen J, Kiparaki M, Baker N. Cell competition removes segmental aneuploid cells from drosophila imaginal disc-derived tissues based on ribosomal protein gene dose. Elife. 2021;10:e61172.

Article CAS PubMed PubMed Central Google Scholar

Tseng CY, Burel M, Cammer M, Harsh S, Flaherty MS, Baumgartner S, et al. chinmo-mutant spermatogonial stem cells cause mitotic drive by evicting non-mutant neighbors from the niche. Dev Cell. 2022;57:8094.

Article CAS PubMed Google Scholar

Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 2010;8:e1000324.

Article PubMed PubMed Central Google Scholar

Bondar T, Medzhitov R. p53-Mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell. 2010;6:30922.

Article CAS PubMed PubMed Central Google Scholar

Watanabe H, Ishibashi K, Mano H, Kitamoto S, Sato N, Hoshiba K, et al. Mutant p53-expressing cells undergo necroptosis via cell competition with the neighboring normal epithelial cells. Cell Rep. 2018;23:37219.

Article CAS PubMed Google Scholar

Read the original:
To not love thy neighbor: mechanisms of cell competition in stem ... - Nature.com

Rewiring blood cells to give rise to precursors of sperm – Phys.org

Immunophenotypic characterization of pre-migratory Callithrix jacchus primordial germ cells (cjPGCs) at embryonic day (E)50. (A) Bright field images of a cj embryo at E50 (Carnegie stage [CS]11). Scale bar, 1 mm. (B) (Left) Immunofluorescence (IF) images of the hindgut in the cj embryo as in (A) (transverse section), stained as indicated. Laminin outlines the basement membranes of the hindgut endoderm. The white dashed line highlights the hindgut endoderm. Scale bars, 50 m. (Right) Pie chart showing the number and location of cjPGCs present in representative cross sections. (C) IF of the same cj embryo for TFAP2C (green), SOX17 (red), PDPN (cyan), and DAPI (white). Magnified images of hindgut endoderm are shown at the bottom. Arrows denote nuclei of cjPGCs with lower DAPI intensity than that of surrounding endodermal cells. Scale bar, 50 m. (D) (Top) IF of the cj embryo stained for MKI67 (green), NANOG (red), and PDPN (cyan), merged with DAPI (white). An arrowhead indicates MKI67+ cjPGC. (Bottom) Pie chart showing the number of MKI67+ cells in PGCs. Scale bars, 50 m. (E) IF of the cj embryo for pre-migratory PGC markers (POU5F1 [green], SOX17 [red], and NANOG [red]) or gonadal stage PGC markers (DDX4 [red] and DAZL [green]), co-stained for PDPN (cyan). Merged images with DAPI (white) are shown on the right of each panel. Scale bars, 50 m. (F) IF of the cj embryo for PDPN (cyan), co-stained for H3K27me3 or H3K9me2 (green). Scale bars, 50 m. Relative fluorescence intensities of H3K27me3 and H3K9me2 in PDPN+ cjPGCs in comparison to those of surrounding somatic cells are shown on the left of each IF panel. Bar, mean. Statistical significance is determined by two-tailed Welchs t test. Credit: eLife (2023). DOI: 10.7554/eLife.82263

Different cell typessay, heart, liver, blood, and sperm cellspossess characteristics that help them carry out their unique jobs in the body. In general, those characteristics are hard-wired. Without intervention, a heart cell won't spontaneously transform into a liver cell.

Yet researchers from the University of Pennsylvania School of Veterinary Medicine, working with collaborators from the University of Texas at San Antonio and Texas Biomedical Research Institute, have prompted marmoset blood cells to acquire the flexibility of stem cells. Then they directed those stem cells to take on the characteristics of sperm precursors.

In the journal eLife, the researchers report on their step-by-step process of rewiring cells. The findingsthe first in the marmoset, a small monkeyopen new possibilities for studying primate biology and developing novel assisted reproductive technologies like in vitro gametogenesis, a process of generating germ cells, sperm or eggs, in a laboratory dish, akin to how in vitro fertilization involves the generation of an embryo outside the human body.

"Scientists know how to generate functional sperm and egg from induced pluripotent stem cells in mice, but mouse germ cells are very different from human germ cells," says Kotaro Sasaki, an assistant professor at Penn Vet. "By studying marmosets, whose biology more closely resembles ours, we can bridge the gap."

To understand how to generate germ cells, the researchers first studied germ cell precursors from marmoset embryos, which had never been rigorously characterized for the species. They found that these early-stage cells, known as primordial germ cells (PGCs), bore certain molecular markers that could be tracked over time.

Performing single-cell RNA sequencing on these cells revealed that PGCs expressed genes characteristic of early-stage germ cells and those related to epigenetic modifications, which regulate gene expression. PGCs did not, however, express genes known to be turned on later in the process of germ cell development, when precursor cells migrate to the ovaries or testes to complete their maturation.

Their findings were "consistent with the notion that marmoset germ cells undergo a reprogramming process," Sasaki says, that "turns off" certain markers and allows PGCs to proceed through the stages of germ cell development. The patterns the researchers observed in marmoset cells closely resembled what has been found in both humans and other monkey species but were distinct from those of mice, another reason why the marmoset could be a valuable model for reproductive biology studies.

With that information in hand, the team set about trying to reconstitute the process of development artificially, in the lab. The first step: to transform blood cells into induced pluripotent stem cells (iPSCs), cells that retain the ability to give rise to a number of other cell types.

"I have a lot of experience in working with cell culture and induced pluripotent stem cells, but establishing a stable culture for the marmoset cells was a difficult part of the study," says Yasunari Seita, a postdoctoral researcher in Sasaki's lab and a lead author.

After much trial and error and applying lessons learned from mouse, human, and other investigations, Seita landed upon a strategy that enabled him to generate and sustain stable cultures of iPSCs. A key to success was the addition of an inhibitor of the signaling pathway governed by the Wnt protein, which is involved in a variety of cellular functions, such as cell differentiation.

The next step was to move from iPSCs to germ cell precursors. Once again, considerable experimentation went into developing the protocol for this transformation. The method that worked best involved adding a cocktail of growth factors to successfully prompt between 15-40% of their culture to take on the characteristics of these germ cell precursors.

"We were excited to see that efficiency and were able to expand our cultures, passaging them multiple times and seeing nice, exponential growth," Sasaki says. "The cells maintained key germ cell markers but didn't express other markers that are associated with the migration to the gonad.

In a final stage of the study, the research team coaxed these lab-grown cells to take on the characteristics of later-stage germ cells. Based on a method Sasaki and colleagues had established earlier in human cells and reported in a 2020 Nature Communications paper, they cultured the cells with mouse testicular cells over the course of a month. The result was a successful growth with some cells beginning to turn on genes associated with later-stage sperm cell precursors.

Developing new approaches to study the marmoset sets up the Penn and University of Texas at San Antonio teamsas well as the scientific community in generalto make use of the species as an important research model. Marmosets, for example, have cognitive functioning that resembles that of humans in many ways and thus could lead to new insights in neuroscience.

For Sasaki's group, most interested in development of the reproductive system, marmosets represent a new avenue for pursuing studies of normal and abnormal development as well as fertility.

"When you think about the clinical applications of an assisted reproductive technology like in vitro gametogenesis, there are a lot of ethical, legal, and safety concerns that could arise," Sasaki says. "We definitely need a good preclinical model to explore before we move to human clinical translation."

More information: Yasunari Seita et al, Efficient generation of marmoset primordial germ cell-like cells using induced pluripotent stem cells, eLife (2023). DOI: 10.7554/eLife.82263

Journal information: eLife , Nature Communications

Follow this link:
Rewiring blood cells to give rise to precursors of sperm - Phys.org

The amazing ways electricity in your body shapes you and your health – New Scientist

Your cells crackle with electric signals that guide embryonic development and heal wounds. If we can learn to tweak this bioelectric code, we might be able to prevent cancer and even grow new limbs

By Sally Adee

Spooky Pooka

WHEN Dany Adams first played back the footage, there was nothing to see. The tadpole had developed enough of a tail to swim out of shot, leaving only a blank screen. Oh well, she remembers thinking. Another one bites the dust. But the camera had been running all night, so she dutifully rewound the tape on the off chance it had caught something interesting. Interesting didnt begin to describe what she saw. My jaw dropped, right to the floor, she says.

The video showed a frog embryo busily dividing to become a tadpole. Then, this tiny, smooth blob began to light up. Electrical patterns flashed a series of unmistakable images across it: two ears, two eyes, jaws, a nose. These ghostly projections didnt last long. But 2 or 3 hours later, exactly where they had glimmered, the real things appeared: two ears, two eyes, jaws, a nose. Here, at last, was the proof she had been after in her role on a decade-long project undertaken by Michael Levin at Tufts University in Massachusetts. It showed that electrical patterns provide a blueprint that shapes a developing body, coordinating where to put its face and grow its other features.

Astounding as this sounds, it is just one of many roles that electricity plays in biology. There is mounting evidence that, as well as instructing development, electricity influences everything from wound healing to cancer. Bioelectric gradients and communication are fundamental to being alive, says Levin. If we can map this electrome and learn to decode it, some astonishing consequences for our health would only be the start.

If you have ever spared a

Original post:
The amazing ways electricity in your body shapes you and your health - New Scientist

iPSC Characterization Kit Market Size, Share and Trends Analysis to 2030 – openPR

iPSC Characterization Kit Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Value-Based Healthcare Services Market By Type (Alkaline Phosphatase Staining Assay, Pluripotency Markers (Protein) And Pluripotency Markers (Mrna)), Application (Cancer Research Center, Pathology Laboratory, Academic And Research, Contract Research Organizations And Others)- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

The global iPSC characterization kit market is estimated to exhibit a CAGR of 6.87% during the forecast period.

Get Free Sample Copy of Report :https://www.insightaceanalytic.com/request-sample/1418

The iPSC characterization kit (Induced pluripotent stem cell) contains several delicate tools for phenotypic characterization of the pluripotent state of human embryonic stem & induced pluripotent stem cells. Induced pluripotent stem cells (iPSCs) have several benefits over embryonic stem cells (ESCs), including avoiding ethical issues with stem cells and providing the most flexibility for use in cell-based research. In recent years, these advantages have significantly increased the popularity of induced pluripotent stem cells (iPSCs), creating a promising market for iPSC characterization kits. The robust pipeline for iPSC-derived cell treatments and innovative iPSC applications is anticipated to hasten market expansion. Furthermore, a rise in the incidence of chronic diseases is contributing to the market growth for iPSC characterization kits. The market for iPSC characterization kits is being driven by the use of induced pluripotent stem cells to treat chronic diseases like diabetes, cancer, cancer, and heart disease. This rise in the incidence of chronic diseases is fueling the rising need for induced pluripotent stem cell therapy, which supports the growth of the iPSC characterization kit market.

List of Prominent Players in the IPSC Characterization Kit Market:Merck KGaATakara BioThermo Fisher ScientificBD BiosciencesApplied StemCellAmsbioBio-TechneALSTEMSTEMCELL TechnologiesSystem BiosciencesApplied Biological MaterialsCreative BioarrayElixirgen ScientificMiltenyi Biotec

Market Dynamics:Drivers- The market for iPSC characterization kits is driven by the expanding utilization of induced pluripotent stem cells (iPSCs), the developing biotechnology sector with better investment, and the rising prevalence of chronic diseases. The broad range of clinical applications of induced pluripotent stem cells and recent technological developments of iPSCs are two additional reasons that are projected to fuel the expansion of the global iPSC characterization kit market.

ChallengesThe availability of alternatives for tumor therapy and the high cost of stem cell therapies are two factors restraining the growth of the worldwide iPSC characterization kit market. The main market hurdle in the global iPSC characterization kit market is the strict laws and regulations and the genomic instability of iPSC. Induced pluripotent stem cell growth is significantly constrained by the possibility of tumor development, which also inhibits the market expansion for iPSC characterization kits.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1418

Regional Trends:The North American iPSC characterization kit market is expected to register a significant market share in revenue and is projected to grow at a high CAGR shortly. Significant commercial and public finance for research institutes is fundamental in this situation, and essential industry firms are well represented in the region. Additionally, a robust R&D infrastructure and various application scenarios, such as tissue engineering and toxicity screening, support the market growth for iPSC characterization kits. It is anticipated that the area will continue to dominate. Besides, Asia Pacific had a substantial share in the iPSC characterization kit market. The adoption of induced pluripotent stem cells is predicted to be supported by robust market expansion in countries like Japan and China and increased interest in regenerative medicine in the region, which will further fuel the growth of the iPSC characterization kit market. Regional governments are working together to change the fact that there isn't a clear legal framework for the iPSC industry. Their efforts will be anticipated to aid in the market growth for iPSC characterization kits.

Segmentation of iPSC Characterization Kit Market-By Type-Alkaline Phosphatase Staining AssayPluripotency Markers (Protein)Pluripotency Markers (mRNA)By Application-Cancer Research CenterPathology LaboratoryAcademic and ResearchContract Research OrganizationsOthersBy Region-North America-The USCanadaMexicoEurope-Germany The UKFranceItaly Spain Rest of EuropeAsia-Pacific-ChinaJapan IndiaSouth KoreaSouth East AsiaRest of Asia PacificLatin America-BrazilArgentinaRest of Latin America Middle East & Africa-GCC CountriesSouth Africa Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/1418

Corporate Office :Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :344 Grove St Unit #967 Jersey City, NJ 07302info@insightaceanalytic.com

info@insightaceanalytic.comNorth America:+1 551 226 6109Asia:+91 79 72967118

This release was published on openPR.

Read more:
iPSC Characterization Kit Market Size, Share and Trends Analysis to 2030 - openPR

Epigenetic Regulation Studied at the Single-Molecule Level – Technology Networks

Register for FREE to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

In a first-of-its-kind study, EMBL researchers have shown how DNA methylation across the genome contributes to the precise regulation of gene expression.

If one imagines the genome as an instruction manual for the functioning of a cell, every page of this manual is covered with annotations, highlights, and bookmarks. The role of some of these marks remains mysterious do they actively direct the reader to the right place at the right time, or do they merely indicate the pages the reader has already visited?

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

This subtle distinction in the language of the cell can play an important role in its survival and function. As researchers from theKrebs groupat EMBL Heidelberg have now shown, one such annotation DNA methylation exerts a highly selective layer of control on the expression of genes, one that varies according to cell type and fate.

In the analogy above, the annotations, highlights, and bookmarks represent what scientists call epigenetic marks, whereas the reader is usually the complex molecular machinery responsible for gene expression. The latter includes specialised proteins known as transcription factors.

When a particular region of DNA needs to be expressed, the area surrounding it undergoes physical and chemical changes, making it more accessible to such molecular machines. While DNA methylation is found across the genome, whether and how it affects this accessibility at specific genomic regions remains relatively unexplored.

Our group is interested in the fundamental mechanisms that regulate gene expression, said Arnaud Krebs, Group Leader at EMBL Heidelberg. We are particularly interested incis-regulatory elements like enhancers DNA regions that control the activity of genes.

Krebs team was intrigued by the fact that while DNA methylation is often reduced at active enhancers, the cause-effect relationship between the two remains unclear. Does the activation of these DNA regions lead to a removal of methylation? Or does the reduction in methylation itself drive the activation?

To investigate this, the team used a high-resolution technique developed in their lab single-molecule footprinting. This method allowed them to simultaneously measure DNA methylation, accessibility, and transcription factor binding, at the level of single DNA molecules. They applied this across the whole genome in multiple cell types, including mouse embryonic stem cells and differentiated cells. This combination of scale and resolution allowed the scientists to gain a deeper understanding of DNA methylations role in gene regulation in a living cell.

The team found that while the accessibility of ~97% of the enhancers they studied was insensitive to DNA methylation, about 3% required the absence of DNA methylation to get activated. At these sites, methylation reduced DNA accessibility and directly prevented the binding of transcription factors. The identity of these methylation-sensitive enhancers varied across cell types and stages.

The 3% of enhancers that seem to be regulated by DNA methylation are enriched for cell-type specific enhancers. We think they are connected to genes that are important for cellular identity, said Elisa Kreibich, PhD student in the Krebs group and first author of the study,now published inMolecular Cell.

By making our measurements at the level of single molecules, we can figure out the connections and interactions between the layers of gene regulation that exist in a cell, added Krebs. While DNA methylation has often been used as a marker for cellular processes, including those involved in cancer, our study shows where it is truly instructive, rather than simply indicative.

Reference: Kreibich E, Kleinendorst R, Barzaghi G, Kaspar S, Krebs AR. Single-molecule footprinting identifies context-dependent regulation of enhancers by DNA methylation. Molecular Cell. 2023. doi: 10.1016/j.molcel.2023.01.017.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
Epigenetic Regulation Studied at the Single-Molecule Level - Technology Networks

On this date: Dolly the Sheep meets the world – ABC27

EDINBURGH, SCOTLAND (WHTM) It was an achievement that many scientists believed was impossible. On Feb. 22, 1997, a scientific team headed by Professor Ian Wilmut at the Roslin Institute, part of the University of Edinburgh, introduced Dolly the Cloned Sheep to the world.

The misconceptions, misconstruals, misinterpretations, misapprehensions, and misoneisms started almost immediately.

A lot of people thought Dolly was the first animal to be cloned, ever. In fact, the first successful clonings, of frogs and fish, were done in the 1950s and 1960s. And as the Rosling Institute explains on its website, Dolly was not even the first cloned mammal.

That honour belongs to another sheep which was cloned from an embryo cell and born in 1984 in Cambridge, UK. Two other sheep, Megan, and Morag, had also been cloned from embryonic cells grown in the lab at The Roslin Institute in 1995 and six other sheep, cloned from embryonic and fetal cells, were born at Roslin at the same time as Dolly.

So what was it about Dollys birth that caused such excitement? She was the first mammal cloned from an adult cell. The process, called Somatic Cell Nuclear Transfer, starts by removing the genetic material from an egg cell, then replacing it with the genetic material from a different animal.

Dolly was cloned using genetic material from a mammary gland cell of a six-year-old Finn Dorset sheep, implanted into an egg cell from a Scottish Blackface sheep. Another Scottish Blackface served as her surrogate mother. When she was born on July 5, 1996, Dollys had the white face of a Finn Dorset, rather than the black face of her surrogate mother, proof she was indeed a clone. Because Dollys DNA came from a mammary gland cell, the research team named her after Dolly Parton. Science humor

The big breakthrough within the big breakthrough was that they did this with a specialized cell. An embryo starts out as a single cell. As the cell divides, and the embryo starts to grow, the cells start to differentiate, becoming, heart cells. liver cells, lung cells, brain cells, mammary gland cells-cells that specialize to perform a specific purpose. Dolly proved it was possible to reset the clock and make an adult cell act like a newly fertilized embryo.

The implication was that it would be possible to take a cell culture from, say, a prize cow, chicken, or sheep, and produce dozens, hundreds, thousands, or even millions of precise duplicates.

The other implication was that you could use human cells to create a clone army.

The pro and con arguments about cloning continue to this day, even though the type of cloning used to create Dolly has pretty well fallen by the wayside. As it turned out, Somatic Cell Nuclear Transfer had a low success rate. Dolly was the only animal born out of 277 cloned embryos, and years of research failed to improve the percentage of viable clones. And in the meantime, a better method was developed- Induced Pluripotent Stem Cells, or iPSC.

The technology of iPSC was developed by Japanese scientists Shinya Yamanaka and Kazutoshi Takahashi. In the early 2000s, they discovered by taking an adult cell and adding a few special genes, the cell would revert to an unspecialized form-a stem cell. The discovery has revolutionized genetic research while avoiding some of the ethical quandaries of SCNT cloning.

Stay up to date on the latest from abc27 News on-air and on the go with thefree abc27 Mobile app.

As for Dolly herself, she continued living a normal sheepish life at the Roslin Institute. She had six lambs with a Welsh Mountain ram called David; Bonnie 1998, twins Sally and Rosie in 1999, and triplets Lucy, Darcy and Cotton in 2000.

Soon after giving birth to the triplets, The institute suffered an outbreak of a virus called Jaagsiekte sheep retrovirus (JSRV), which causes lung cancer in sheep. Dolly was one of those infected. In February 2003, Dolly developed a cough, and a CT scan showed tumors in her lungs. Rather than allow her to suffer, the Institute put Dolly to sleep onFeb. 14, 2003, at the age of six.

Six years old is about half the usual lifespan of a sheep. When Dolly was a year old, the team at the Institute ran an analysis of her DNA and discovered her telomeres, the caps found at the end of chromosomes, were shorter than they should be for sheep of that age. Telomeres protect the DNA in chromosomes from damage, and get shorter as an organism ages. When Dolly died, it was widely presumed her short telomeres were (a) a result of cloning, and (b) at least partly responsible for her early demise-in effect, she was older than her years.

However, as the Roslin Institute website reports, extensive health screens on Dolly at the time did not find any conditions which could be directly related to premature or accelerated aging. And studies of cloned animals have found shorter, longer, and normal telomeres. So its hard to prove Dollys early death was directly related to cloning.

Since 2003, Dolly has been on display at the National Museum of Scotland in Edinburgh. Twenty years later, shes still one of their most popular exhibits.

For a list of animals that have been cloned, click here.

Read the original here:
On this date: Dolly the Sheep meets the world - ABC27

"Cell Therapy Market to Surpass $7,754.89 Million, by 2027, Fueled by Growing Investments in Research and Deve – openPR

, $7,754.89 2019, $48,115.40 2027, 25.6% 2020 2027. Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, owing to their ability to differentiate into specific cells required for repairing damaged or defective tissues or cells.

Cell therapy is being increasingly used in the development of regenerative medicine, which involves the repair, replacement or regeneration of cells, tissues or organs that are damaged or diseased. Regenerative medicine is a multidisciplinary field that uses a combination of approaches, including stem cell therapy, tissue engineering, and gene therapy.

https://www.alliedmarketresearch.com/request-sample/5330

There are various types of cells that are used in cell therapy procedures, including blood and bone marrow cells, mature and immature tissue cells, adult stem cells, and embryonic stem cells. Transplanted cells such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are classified into two main groups, autologous cell therapy and non-autologous cell therapy.

Autologous cell therapy involves using a patient's own cells, which are collected, processed, and then re-administered back to the patient. Non-autologous cell therapy involves using cells from a donor, which are collected, processed, and then administered to the patient. The choice of autologous or non-autologous cell therapy depends on various factors, including the type of disease or condition being treated, the availability of suitable donor cells, and the patient's individual needs and preferences.

COVID-19 pandemic has had a significant impact on the cell therapy market. The widespread adoption of lockdown measures in many countries has led to a reduction in the number of clinics that are able to undertake new cases of stem cell therapy, organ transplant, and other treatments. This has resulted in a slowdown in the development and commercialization of new cell therapies.

In addition, many biopharmaceutical companies, including major players such as Pfizer and Eli Lilly, have announced clinical trial delays due to the pandemic. This has led to a delay in the approval and launch of new cell therapies, which has further contributed to the slowdown in the market.

The impact on allogeneic cell therapies, which are derived from a healthy donor, is particularly acute, as the pandemic has led to a shortage of donor cells and a disruption in the supply chain for these therapies. This has led to a delay in the development and commercialization of allogeneic cell therapies, which has further contributed to the slowdown in the market.

Financing and investments have played a significant role in driving the growth of the cell therapy market, and this trend is expected to continue in the coming years. The development of new companies in the industry is expected to boost organic revenue growth, as these companies bring innovative technologies and therapies to the market.

One example of such investment is Bayer's investment of $215 million in July 2019 for the launch of Century Therapeutics, a U.S.-based biotechnology start-up focused on developing therapies for solid tumors and blood cancer. This investment was aimed at supporting the development of new cell therapies and providing funding for clinical trials. Later, additional funding of $35 million from Versant Ventures and Fujifilm Cellular Dynamics was added to the financing, which is expected to further boost the market growth.

This kind of investment in the industry is expected to drive the development of new and innovative cell therapies, which will lead to increased adoption of these therapies in the treatment of various diseases and medical conditions. It is anticipated that the market will continue to attract significant investments and financing in the coming years, which will further accelerate the growth of the cell therapy market.

:https://www.alliedmarketresearch.com/purchase-enquiry/5330

1.By Cell Type: This refers to the type of cells used in the therapy. The different types of cells include stem cells (such as bone marrow, blood, umbilical cord-derived, adipose-derived stem cells, placenta, and nonspecific cells) and non-stem cells.

2.By Therapy Type: This refers to whether the therapy is autologous (using the patient's own cells) or allogeneic (using cells from a donor).

3.By Therapeutic Area: This refers to the medical conditions that the therapy is used to treat. Examples of therapeutic areas include malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

4.By End User: This refers to the type of institution or organization that uses the therapy. The main end users are hospitals and clinics, and academic and research institutes.

5.By Region: This refers to the geographic regions where the therapy is used or sold. The main regions are North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

1.ALLOSOURCE2.CELLS FOR CELLS3.HOLOSTEM TERAPIE AVANZATE SRL4.JCR PHARMACEUTICALS CO.5.KOLON TISSUEGENE6.MEDIPOST CO.7.MESOBLAST LTD8.NUVASIVE9.OSIRIS THERAPEUTICS10.STEMEDICA CELL TECHNOLOGIES

?1.What is cell therapy, and how does it work?

2.What are the different types of cells used in cell therapy, and what medical conditions can they treat?

3.What are the main applications of cell therapy in modern medicine?

4.What is the current size of the cell therapy market, and what is the expected growth rate in the coming years?

5.What are the main drivers of growth in the cell therapy market, and what are the main challenges facing the industry?

6.What are the regulatory requirements for the development and approval of cell therapies, and how do they vary by region?

7.What are the main companies involved in the development and commercialization of cell therapies, and what are their competitive strategies?

8.What are the main trends and innovations in cell therapy research and development?

9.How do autologous and allogeneic cell therapies differ, and what are the advantages and disadvantages of each approach?

10.What are the main end-users of cell therapy products and services, and how do their needs and preferences shape the market?

https://www.alliedmarketresearch.com/checkout-final/435ed417be65921756bfb923bfd57c8a

:

pharmacogenomics markethttps://www.alliedmarketresearch.com/pharmacogenomics-market

Artificial Intelligence for Drug Discovery and Development Markethttps://www.alliedmarketresearch.com/artificial-intelligence-for-drug-development-and-discovery-market

Laboratory Equipment and Disposables Markethttps://www.alliedmarketresearch.com/laboratory-equipment-and-disposables-market

Ophthalmic Viscoelastic Devices (OVD) Markethttps://www.alliedmarketresearch.com/ovd-market

Menstrual Cup Market https://www.alliedmarketresearch.com/menstrual-cup-market

General Anesthesia Drugs Markethttps://www.alliedmarketresearch.com/general-anesthesia-drugs-market

Mobile Gamma Cameras Markethttps://www.alliedmarketresearch.com/mobile-gamma-cameras-market

Immunosuppressants Markethttps://www.alliedmarketresearch.com/immunosuppressants-market

Hybrid Operating Room Markethttps://www.alliedmarketresearch.com/hybrid-operating-room-market

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975help@alliedmarketresearch.comWeb: https://www.alliedmarketresearch.com

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Read this article:
"Cell Therapy Market to Surpass $7,754.89 Million, by 2027, Fueled by Growing Investments in Research and Deve - openPR

UC researchers developing method to repair hearts – EurekAlert

The regeneration and repair of cells that have been damaged in heart attacks could be possible in the future thanks to research at the University of Cincinnati.

When a person suffers a heart attack, also called a myocardial infarction, millions of heart muscle cells are starved of oxygen and die. Once the cells in the heart die, theres no natural system in the human body to replace them.

Yigang Wang, MD, director of the regenerative medicine division in UC's College of Medicine, is leading the development of a technique using something called a cell patch that could regenerate cells following a heart attack.

A cell patch is a lab-grown patch of muscle that would be affixed to the damaged area of the heart following a heart attack. The patch would replace the damaged cells and allow the heart to repair itself.

The problem with the current paradigm is that theres really not much that they can do except treat your symptoms, said Christian Paul, a research assistant in Wangs lab. Treating your symptoms isnt going to repair anything.

Within the heart are cells called cardiomyocytes, which are responsible for the beating and contraction of the heart. During a heart attack, those cells can be starved of oxygen and die.

When cardiomyocytes die, they lose their ability to contract and pump blood.

After a heart attack, those original cells are lost or become fibroblasts, Wang said. Then we could convert them to the original cells. That would be ideal to repair a myocardial infarction.

Wangs research is in the early stages, having done experiments in cell dishes and small animal models that have shown promise. In the future, breakthroughs that have been developed in the lab could help people avoid open heart surgery and receive better care.

If humans could regenerate the scarred area of the damaged heart into viable heart cells, less invasive procedures would be needed.

Our method, if in the future it could be used in the clinic, would be revolutionary, Wang said.

The cell patch, which Wang likened to a sandwich with multiple layers of cells, would include cardiomyocytes, fibroblasts, smooth cells and endothelial cells.

Fibroblasts are cells that contribute to the formation of connective tissue. They support the cells around them but cant pump blood.

Endothelial and smooth cells form new blood vessels, delivering nutrients to the damaged tissue, and remove waste. While the researchers at UC and worldwide have worked to develop cell patches, and been hopeful of their potential, there have been impediments to making cell patches a viable treatment.

Many cells, whether you inject them or put a cell patch on it, after a week, 98% of the cells die, Wang said.

To overcome these challenges, the UC researchers have developed new techniques and products.

To create new cardiomyocytes, the researchers use stem cells that are derived from skin or blood cells and reprogrammed into an embryonic-like state that allows the development of any type of human cell needed. The UC researchers have developed ways to make the cells mature quicker.

Wang and his team used CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology a genome editing system to alter genes.

By activating reprogramming genes in the body, their new approach turns heart scar tissue into cardiomyocytes. Also, by inhibiting a certain gene, these cells can continue to multiply, and the damaged cells can rejuvenate.

Additionally, they created a new hydrogel. The hydrogel, which Paul compared to a glue, attaches the cell patch to the heart.

The hydrogel developed at UC would introduce oxygen and growth factors, creating the best possible environment for cells to develop.

The UC team has patented its new products and techniques with the help of the staff at UCs Tech Transfer team at the 1819 Innovation Hub, which has given them more time to focus on their work.

Theyve been awesome, Paul said. Most of the paperwork and administrative aspects, theyve taken care of, and theyve asked us for the basic information and taken it from there.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
UC researchers developing method to repair hearts - EurekAlert

At OurCrowd Summit, Startup Has High Hopes for COVID-busting … – The Media Line

Leading MedTech and FoodTech startups converge on international investors summit in Jerusalem, as buyers and sellers come together to check out latest technological innovations

After its pandemic success, Israeli-Canadian startup SaNOtize is hoping that clinical trials will show that its pioneering antiviral nasal spray can be used to treat the flu and other upper respiratory viruses.

The nitric oxide spray, called Enovid, has been proven to effectively prevent, treat and shorten the course of a COVID-19 infection.

Nitric oxide kills bacteria, viruses, fungi and we have a way to deliver it, Dr. Gilly Regev, CEO and co-founder of SaNOtize, told The Media Line. Instead of pressurized gas cylinders we deliver it in liquids. You can deliver it at the right dose and at the right place to get rid of bacteria, viruses and fungi.

A report published in the prestigious British peer-reviewed The Lancet medical journal last year showed that when used six times daily over a one-week period, the spay effectively reduced SARS-CoV-2 RNA in the nasal cavity by roughly 94 percent in 24 hours, and 99% in 48 hours. The study was carried out in clinical sites across India during the delta and omicron surges.

Weve done some clinical trials, double-blind placebo trials treating people who already have very high viral loads and we showed that we can reduce the viral load significantly, Regev affirmed, adding that the nitric oxide led to those infected with COVID recovering twice as fast as control groups.

Enovid has already been approved and is for sale in dozens of countries around the world, and now SaNOtize has its eyes set on combating yet another widespread virus: influenza.

What were going to do next is do clinical trials with flu, Regev said.

Regev spoke to The Media Line on the sidelines of the 2023 OurCrowd Global Investor summit, which took place in Jerusalem last week. The summitIsraels largest investor eventsaw more than 9,000 people from around the world take part in lectures, briefing, networking sessions and startup exhibitions on a wide variety of tech-related topics.

Among the many MedTech startups making waves at the event was Binah.ai, which has developed an artificial intelligence-based platform that detects vital signs using a cell phone camera.

The platformwhich is about to receive FDA approvalcan read a persons heart rate, blood pressure and even hemoglobin levels by simply scanning their face.

We are working today with 11 out of the top 100 insurance companies in the world, including Sompo from Japan, Generali in Germany, MetLife in Malaysia and quite a few other countries, David Maman, CEO and founder of the startup, told The Media Line.

In terms of accuracy, Maman said that everything is aligned to be medically approved, which means that they meet the requirements for an FDA submission.

FoodTech was another significant arena featured at the summit.

Mermade Seafoods, for instance, has found a way to cultivate scallops using fewer resources than traditional aquaculture. The company is hoping to disrupt the $8 billion global scallops market with its technology.

We cultivate cells, basically taking embryonic stem cells and cultivating them, said Daniel Einhorn, CEO and co-founder of the startup.

Other FoodTech innovators were looking at ways to make popular foods healthier.

Blue Tree Technologies has developed a method to remove sugar from natural fruit juices using a patented technology that extracts disaccharides from liquids.

The technology is based on a procedure in which we filter the juice and then the juice runs through a column with a special mineral that acts like a magnet, Michael Gordon, CEO of Blue Tree Technologies, told The Media Line. The magnet is taking the disaccharide from the beverage itself.

The amount of sugar removed depends upon a clients needs, he added. Blue Tree has partnered with leading Israeli juice manufacturer Priniv and its products are set to hit supermarket shelves in the country by the end of year.

When you remove sugar from beverages then manufacturers pay less taxes so everyone wins, Gordon said.

Whether it is antiviral treatments, AI-based healthcare or reducing peoples sugar intake, the OurCrowd summit brought together some of the worlds leading entrepreneurs and tech experts, many of whom have come up with visionary solutions to some of humanitys most pressing problems.

Here is the original post:
At OurCrowd Summit, Startup Has High Hopes for COVID-busting ... - The Media Line